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Abstract
Background: Women with cardiac disease are thought to be at increased risk of post-partum haemorrhage. We
sought to assess the estimated blood loss (EBL) in our cohort of women with and without cardiac disease (CD) in a
quaternary hospital in the UK. Our population consisted of both congenital and acquired CD; and low risk women
who delivered in our unit between 01/01/2012–30/09/2016.
Methods: Data were collected using computerised hospital records. CD was classified according to the modified
WHO classification (mWHO). The primary outcome measure was estimated blood loss (mL).
Results: A total of 5413 women with a singleton fetus in the cephalic presentation delivered during the study
period (159 women with CD and 5254 controls). In the CD group, active management of the third stage of labour
was consistent with that used in low risk women in 98% (152/155) of cases. Multivariable analyses demonstrated no
significant difference in EBL between women with CD vs controls. The adjusted average blood losses were 247.2 ml,
241.8 ml and 295.9 ml in the control group, mWHO 1–2 and 3–4, respectively (p = 0.165).
Conclusions: Women with CD have comparable EBL to low risk women when management of the active third
stage of labour is the same.
Background
Women with heart disease may tolerate post-partum haem-
orrhage (PPH) poorly, because of a reduced ability to com-
pensate for rapid changes in circulating volume. Two factors
in the intrapartum management of these women may in-
crease their risk of PPH. Firstly, concern about their ability
to increase cardiac output during the active second stage of
labour has led obstetricians to limit the duration of this stage,
resulting in an increased chance of instrumental delivery and
PPH. Secondly, because of their cardiovascular effects, re-
duced doses of oxytocic drugs in the third stage of labour
are often used in women with heart disease, increasing the
risk of PPH [1, 2]. Oxytocin is a nanopeptide with homology
to anti-diuretic hormone. Animal and human models of
cardiovascular response to oxytocin have demonstrated a
hypotensive effect when intravenous administration occurs
too rapidly [3]. In all pregnant women with cardiac disease,
the Royal College of Obstetricians and Gynaecologists
(RCOG) advocates 5 i.u Syntocinon intramuscularly (im) or
2 i.u. intravenous (iv) over 10min for active management of
the third stage [1]. The European Society for Cardiology
(ESC) echoes the RCOG recommendation of using 2 i.u oxy-
tocin iv, but makes no mention of intramuscular oxytocin
use [4]. These doses are half of those used in healthy women
for active management of the third stage [5].
Cauldwell et al. identified a higher mean blood loss at
delivery in 366 nulliparous women with congenital cardiac
disease, compared to nulliparous women without cardiac
disease. They found that the mean blood loss was 439mLs
for spontaneous vaginal delivery, 715 mLs after forceps
delivery, 722 mLs after emergency caesarean section (CS)
and 854 mLs for those who underwent a general anaes-
thetic [6]. As no information on uterotonics was provided,
it is difficult to assess if the blood loss was a consequence
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of having heart disease or because of management of the
third stage.
The Birmingham Women’s and Children’s Hospital pro-
vides a quaternary service to women with cardiac disease in
the West Midlands. These are women with congenital and
acquired disease, encompassing both structural and rhythm
abnormalities, as well as ischaemic heart disease. Our ser-
vice is multidisciplinary, with maternal fetal medicine spe-
cialist obstetricians, cardiologists with expertise in
congenital heart disease, obstetric anaesthetists and a spe-
cialist obstetric haematologist. Management of the third
stage is individualised when making their intrapartum care
plan. Our protocol for management of the third stage of
labour in women with cardiac disease is identical to that for
women with low risk pregnancies, unless there is a specific
indication for an alternative regimen. Active management
of the third stage in the low risk and cardiac population is
described in Table 1. In the event of increasing blood loss,
our practice is to administer further uterotonics, in line
with RCOG guidance on PPH, with the exception that
ergometrine is avoided [7]. We sought to evaluate the im-
pact of our practice on estimated blood loss (EBL) following
delivery in this high risk population, and hypothesised that
the EBL in women with cardiac disease would be similar to
women without cardiac disease, as our management of
these two groups is essentially identical [7].
Methods
This was a retrospective cohort study in a quaternary re-
ferral centre. Patients were identified from the cardiac
obstetric database. All women with cardiac disease who
were seen antenatally and delivered at Birmingham
Women’s Hospital from 01/01/2012–30/09/2016 were
included. We included all women with a past medical
history of cardiac disease, carrying singleton pregnancies
and delivering a baby in the cephalic presentation. Car-
diac disease was categorised according to the modified
World Health Organisation (mWHO) classification of
maternal conditions at the start of pregnancy [4]. The
comparator group consisted of women without cardiac
disease who commenced their labour in the adjacent
birth centre in our unit during the same period. The fol-
lowing exclusion criteria were applied to the control
group:
 Any medical disease (such as epilepsy, gestational
diabetes or diabetes mellitus, cardiac disease, liver or
renal disease, hypertension)
 Pre-eclampsia or pregnancy induced hypertension
 Body Mass Index (BMI) > 35 kg/m2
 Malposition
 Malplacentation
 Multiple pregnancy
 Estimated gestational age under 37 weeks
 More than two episodes of reduced fetal movements
 Fetal growth restriction
 Estimated fetal weight over 4.5 kg.
For all patients included in the study, data were extracted
from the departmental records system for age, BMI, parity,
gestation, baby weight and the mode of delivery. Blood loss
was visually estimated, and although this approach has limi-
tations [8], it is standard practice globally.
Statistical methods
Initially, a range of factors were compared across the
mWHO grades, with the control group treated as
“mWHO 0”. Continuous variables were analysed using
Jonckheere-Terpstra tests, to account for the order of
the mWHO grades, whilst nominal variables were
assessed using Fisher’s exact tests. Analyses were then
performed to identify factors associated with blood loss,
using Spearman’s rho correlation coefficients for con-
tinuous variables and Mann-Whitney tests for nominal
variables. The distribution of blood loss was highly
skewed, and so was summarised using both geometric
Table 1 Dose and route of oxytocin for management of the third stage in women with and without cardiac disease in our unit
Oxytocic agents used for active management of the 3rd
stage
Spontaneous
vaginal delivery
Non-rotational
delivery
Rotational delivery
in theatre
Elective or Emergency
Caesarean delivery
All women without cardiac disease in accordance with NICE
guidelines on intrapartum care.
10 i.u. oxytocin, intramuscular (im) 5 i.u. oxytocin intravenous (iv), given as a slow
bolus over 3–5 min
Women with cardiac disease except those listed below. 10 i.u. oxytocin, im 5 i.u. oxytocin iv given as a an infusion over 10
min through a pump
Women with the following cardiac conditions:
• Single ventricle
• Fontan circulation
• Valvar stenosis
• Severely impaired ventricular function [< 30% Ejection
Fraction (EF)]
Management is individualised with consideration of a 5 iu infusion over 10min
through a pump
The key difference in the administration of oxytocin in our population of low risk women and women with cardiac disease is that intravenous administration
occurs over a 10 min interval instead of a slow bolus over 3–5 min. The dose of oxytocin is the same. This regime differs from the RCOG good practice
recommendation which advocates a lower dose of 2 i.u. ocytocin given over 10–20 min at elective CS; and 5 i.u oxytocin intramuscularly, or 2 i.u oxytocin over 10
min for women who have a vaginal delivery
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means and medians with interquartile ranges (IQRs). A
multivariable analysis was then performed to identify
factors that were independently associated with blood
loss. Blood loss values were log2-transformed, prior to
the analysis, to reduce the degree of skew in the distri-
bution and improve model fit. The coefficients from the
resulting model were then anti-logged, and converted
into percentage differences. As such, for continuous var-
iables, the reported values represented the percentage
increase in blood loss associated with a unit increase in
the factor. For nominal variables, the values represented
the percentage difference in blood loss between groups.
Adjusted average blood losses in each group were then
were then calculated, by evaluating the model at the co-
hort mean value of continuous variables, and for the
proportion of patients in each category of nominal vari-
ables. All analyses were performed using IBM SPSS 22
(IBM Corp. Armonk, NY), with p < 0.05 deemed to be
indicative of statistical significance throughout.
Results
Patient demographics
Data were available for a total of 5413 patients who de-
livered between 01/01/2012–30/09/2016. Of these, 5254
(97.1%) were healthy controls, 105 (1.9%) had heart
disease and were mWHO grade 1–2 and 54 (1.0%) had
heart disease who were mWHO grade 3–4 (Table 2).
Patient demographics are compared between these
groups in Table 3. This found that, as mWHO grade in-
creased, there were significant increases in patient age
(p = 0.012), BMI (p < 0.001) and parity (p < 0.001). In-
creasing mWHO grade was also associated with signifi-
cantly shorter gestation (p < 0.001) and, correspondingly,
a significantly lower baby weight (p < 0.001). The mode
of delivery also differed significantly by mWHO grade
(p = 0.002). Spontaneous vaginal delivery made up 77.2%
of cases in healthy controls compared to 42.6% in WHO
grade 3–4, whilst rates of caesarean section increased
from 6.9 to 44.4% across the categories.
Indications for operative vaginal delivery and CS in
women with cardiac disease
Of the 11 women with cardiac disease who underwent
ventouse delivery, the most common indication was a
non-reassuring cardiotocograph (CTG), with this occur-
ring in 73% (8/11) of women. In one (9%) woman, a ven-
touse delivery was performed exclusively for the maternal
cardiac condition, whilst, in another woman (9%), the de-
cision was made in light of a combination of non-reassur-
ing CTG and the maternal cardiac condition. One woman
Table 2 List of cardiac conditions and mWHO classifications
mWHO classification
1 2 3 4 Total
Congenital
Marfan or other aortopathy including bicuspid valve aortopathy – 2 10 1 13
Repaired septal defect (atrial, ventricular, atrioventricular) 2 10 1 – 13
Repaired Tetralogy of Fallot 10 2 – 12
Repaired coarctation of the aorta – 8 1 – 9
Hypertrophic cardiomyopathy – 4 4 – 8
Complex disease, biventricular repair – 5 2 – 7
Systemic right ventricle (congenitally corrected transposition, transposition post atrial switch) – – 5 1 6
Bicuspid aortic valve without aortopathy 4 – – – 4
Transposition of the great arteries, post arterial switch – 4 – – 4
Fontan – – 2 – 2
Othera – 5 5 – 10
Total 6 48 32 2 88
Acquired
Regurgitant valvular lesions 4 13 4 – 21
Arrhythmia (normal echo) 16 5 – – 21
Stenotic valvular lesions 1 4 8 1 14
Dilated cardiomyopathy or previous peripartum cardiomyopathy or other cardiomyopathy 2 1 6 – 9
Ischaemic heart disease 2 3 1 – 5
Total 25 26 19 1 71
a Includes: cardiac transplant, cardiac trauma, cor triatriaum, dilated pulmonary artery, mechanical valve, unoperated atrial septal defect, bioprosthetic valve,
complex cyanotic heart disease
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(9%) required assisted delivery due to maternal exhaustion
alone. Forceps deliveries were performed in 11 of the women
in the cardiac diseases group. Of these, 64% (7/11) were due
to a non-reassuring CTG or abnormal fetal blood sample
(FBS) result, with the remainder (36%, 4/11) being due to
slow progress in the second stage (exceeded 60min of active
pushing). Of the 61 women with cardiac disease that
underwent caesarean sections, 28% (17/61) were ex-
clusively due to their maternal cardiac condition, 19%
(12/61) were undertaken due to prior delivery by CS,
and the remaining women had other obstetric reasons
for CS (Table 4).
Blood loss
Across the cohort as a whole, the median blood loss was
250mL (IQR: 200–350), with a geometric mean of 245.7
mL. Whilst on univariate analysis the EBL was found to be
increased with mWHO grade, multivariate analyses showed
no difference..
Univariable analysis
Blood loss was found to increase significantly with
mWHO grade on univariable analysis (Table 5), with geo-
metric means of 244.4 vs. 276.0 vs. 326.4mL for controls
vs. women with the disease who were mWHO 1–2 vs. 3–
4 (p < 0.001). Blood loss was also found to increase
significantly with age at delivery (p = 0.016), BMI (p=
0.014), gestation (p < 0.001) and baby weight (p < 0.001), and
to decline with parity (p < 0.001). A significant difference
across the modes of delivery was also detected (p < 0.001),
with the greatest blood loss in caesarean sections, and man-
ual removal of the placenta (MROP) was also significantly as-
sociated with increased blood loss (p < 0.001).
Since caesarean sections had been shown to be associ-
ated with high levels of blood loss, and were also more
likely to be performed in women with heart disease, a
subgroup analysis was performed by the mode of deliv-
ery (Table 6). This found no significant difference in the
Table 3 Factors associated with mWHO grade
WHO Grade
N Controls 1–2 3–4 p-Value
Age at Delivery 5413 28.5 ± 5.1 29.4 ± 5.9 30.1 ± 5.8 0.012
BMI 4579 24.4 (21.9–27.6) 26.2 (22.1–31.5) 27.4 (23.8–32.3) < 0.001
Parity 5384 < 0.001
0 2584 (49.3%) 32 (33.0%) 21 (43.8%)
1 1569 (29.9%) 35 (36.1%) 9 (18.8%)
2 664 (12.7%) 17 (17.5%) 10 (20.8%)
3+ 422 (8.1%) 13 (13.4%) 8 (16.7%)
Gestation at Delivery (Completed weeks) 5412 < 0.001a
< 40 Weeks 2088 (39.7%) 79 (76.0%) 45 (83.3%)
40+ Weeks 3166 (60.3%) 25 (24.0%) 9 (16.7%)
Baby Weight (g) 5407 3404 ± 431 3150 ± 641 2741 ± 641 < 0.001
Mode of delivery 5413 0.002b
Spontaneous Vaginal 4054 (77.2%) 53 (50.5%) 23 (42.6%)
Ventouse 309 (5.9%) 9 (8.6%) 2 (3.7%)
Forceps 528 (10.0%) 6 (5.7%) 5 (9.3%)
Caesarean Section 363 (6.9%) 37 (35.2%) 24 (44.4%)
Manual Removal 5413 0.297b
No 5219 (99.3%) 104 (99.0%) 53 (98.1%)
Yes 35 (0.7%) 1 (1.0%) 1 (1.9%)
Data are reported as mean ± SD, median (IQR), or as N (%), as applicable. p-Values are from Jonckheere-Terpstra tests, unless stated otherwise. Bold p-values are
significant at p < 0.05.a The number of weeks gestation was analysed as a continuous variable when calculating the p-value. bFisher’s exact test
Table 4 Indications for Caesarean Section in women with
cardiac disease
Indications for Caesarean Section N (%)
Maternal medical disease 17 (28%)
Previous CS 12 (20%)
Presumed fetal compromise 11 (18%)
Other 6 (10%)
Breech 5 (8%)
Delay 1st stage 5 (8%)
Growth restriction 3 (5%)
Failed induction 2 (3%)
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Table 5 Factors associated with blood loss
N Blood Loss (mL)
Median (IQR) Geometric Mean p-Value
mWHO Grade < 0.001
Controls 5254 250 (177–350) 244.4
1–2 105 300 (200–500) 276.0
3–4 54 400 (200–500) 326.4
Age at Delivery 0.016
< 25 Years 1248 250 (150–350) 240.2
25–29 Years 1831 250 (150–350) 244.1
30–34 Years 1622 250 (200–400) 247.4
35+ Years 712 250 (200–400) 256.0
BMI 0.014
≤ 25 2535 250 (200–350) 244.8
25–30 1455 250 (200–400) 253.2
> 30 589 250 (199–400) 251.5
Parity < 0.001
0 2637 300 (200–400) 281.6
1 1613 200 (150–300) 222.4
2 691 200 (150–300) 209.3
3+ 443 200 (100–300) 199.3
Gestation at Delivery (Completed weeks) < 0.001
< 40 Weeks 2212 200 (150–300) 226.5
40+ Weeks 3200 250 (200–400) 259.9
Baby Weight < 0.001
< 3.0 kg 949 200 (150–300) 213.6
3.0–3.4 kg 2280 250 (150–350) 237.8
3.5–3.9 kg 1705 250 (200–400) 259.0
4.0+ kg 473 300 (200–450) 314.4
Mode of Delivery < 0.001a
Spontaneous Vaginal 4130 200 (150–300) 214.7
Ventouse 320 300 (200–400) 279.7
Forceps 539 350 (250–500) 353.4
Caesarean Section 424 500 (400–700) 521.9
Manual Removal < 0.001b
No 5376 250 (193–350) 244.8
Yes 37 400 (250–700) 416.3
p-Values are from Spearman’s rho correlation coefficients on the untransformed factors, unless stated otherwise. Bold p-values are significant at p < 0.05.
aKruskal-Wallis test. bMann-Whitney test
Table 6 Subgroup analysis by mode of delivery
Vaginala Caesarean Section
N Median (IQR) Geometric Mean p-Value N Median (IQR) Geometric Mean p-Value
mWHO Grade 0.810 0.079
Controls 4891 200 (150–300) 230.6 363 500 (400–700) 535.6
1 + 2 68 200 (150–300) 219.7 37 450 (300–500) 419.5
3 + 4 30 250 (200–400) 234.2 24 500 (400–650) 494.1
p-Values are from Jonckheere-Terpstra tests, and p-values are significant at p < 0.05. aIncludes spontaneous, Ventouse and forceps deliveries
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amount of blood lost between the control and heart
disease groups within the subgroups of patients
undergoing vaginal deliveries (p = 0.810) or caesarean
sections (p = 0.079).
Multivariable analysis
To adjust for other potentially confounding factors, a mul-
tivariable analysis was performed (Table 7). This model
identified increasing age at delivery (p = 0.008) and baby
weight (p < 0.001), parity of 0 (p < 0.001), manual removal
(p < 0.001) and caesarean section (p < 0.001) to be signifi-
cant independent predictors of increased blood loss. After
accounting for these factors, no significant difference in
blood loss between the control group and women with
cardiac disease who were mWHO 1–2 or 3–4 was de-
tected (p = 0.165), with adjusted average blood losses of
247.2 mL, 241.8 mL and 295.9mL, respectively.
Third stage management in women with cardiac disease
Of the women with cardiac disease, 3% (4/159) had a
physiological third stage. Alternative regimes to those de-
scribed in Table 1 were used in 2% (3/159) women [car-
diomyopathy (n = 2), Repaired Tetralogy of Fallot (n = 1)].
Of these three women, only one received a reduced dose
of oxytocin (3 i.u iv instead of 5 i.u.). One patient received
an infusion of oxytocin (20 units in 20 mLs of saline in-
fused over 20min) as the only uterotonic. The other pa-
tient received 5 i.u. of oxytocin, but this was given over 20
min instead of 10min. We speculate that the variations in
the three women were due to clinician uncertainty, as
these women delivered “out of hours”. Only seven women
received Syntometrine as the primary uterotonic. In five of
these women, this occurred prior to the change in NICE
guidelines for intrapartum care in 2014. All other women
had 10 i.u. intramuscular or 5 i.u. intravenous oxytocin for
active management of the third stage, as described in
Table 1, and additional uterotonics as required if there
were concerns about on-going blood loss.
Adverse outcomes in women with cardiac disease
A total of 32 women (20%) received high dependency
care as a result of their cardiac disease, which was part
of standard care for this population. None of the women
with cardiac disease required high dependency care as a
result of blood loss. None of the women with cardiac
disease in our study required balloon uterine tamponade,
Table 7 Multivariable analysis of blood loss
Coefficient (95% CI) p-Value
mWHO Grade 0.165
Controls – –
1–2 −2.2% (−13.9, 11.2%) 0.739
3–4 19.7% (− 1.2, 45.0%) 0.066
Age at Delivery (per Decade) 4.6% (1.2, 8.2%) 0.008
BMI (per 10 kg/m2) 1.0% (−2.9, 5.1%) 0.624
Parity < 0.001
0 – –
1 −11.0% (−14.6, −7.2%) < 0.001
2 −16.9% (−21.4, − 12.3%) < 0.001
3+ −19.9% (− 25.0, − 14.5%) < 0.001
Gestation at Delivery (Completed weeks) −0.1% (− 1.7, 1.5%) 0.889
Baby Weight (per kg) 28.6% (23.4, 34.1%) < 0.001
Mode of Delivery < 0.001
Spontaneous Vaginal – –
Ventouse 23.3% (15.0, 32.3%) < 0.001
Forceps 47.5% (39.2, 56.2%) < 0.001
Caesarean Section 121.1% (107.4, 135.6%) < 0.001
Manual Removal < 0.001
No – –
Yes 59.1% (30.3, 94.1%) < 0.001
Results are from a multivariable general linear model. Blood loss followed a skewed distribution, and so was log2-transformed, before being set as the dependent
variable. The resulting coefficients from the model were anti-logged, and converted into percentage differences. As such, for continuous variables, the reported
values represent the percentage increase in blood loss associated with the stated increase in the factor whilst, for the nominal variables, the values are the
percentage increase in blood loss in the stated group, relative to the reference. After excluding cases with missing data, the final model was based on N = 4573.
Bold p-values are significant at p < 0.05
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B-Lynch sutures or hysterectomy. None of the women
with cardiac disease in our study population experienced co-
agulopathy or organ dysfunction as a result of blood loss.
Only three (2%) women with cardiac disease required a
blood transfusion of 2 units of packed red cells; blood loss in
these women was less than 500mL. All three had cyanotic
heart disease, and were transfused to keep their haemoglobin
above 120 g/L in order to optimise oxygen carrying capacity.
No adverse cardiovascular events were observed after oxyto-
cin administration, as defined by unplanned admission to
HDU or the need for fluid resuscitation.
Discussion
Main findings
In our cohort of nulliparous and multiparous women with
congenital and acquired cardiac disease, we found that the
EBL following delivery was low. After accounting for the dif-
ferences in patient demographics and modes of delivery in
this cohort, EBL was not found to be significantly higher
than the contemporaneously managed low risk women with-
out heart disease. Our results indicate that active manage-
ment of the third stage using a standard uterotonic regime
in cardiac women is safe, beneficial and results in an EBL
comparable to a low risk population. According to NICE
guidelines [5], we advise active management of the third
stage for all women, however, we advocate this more
strongly for women with cardiac disease because of the risk
of cardiovascular instability in the event of a PPH.
In our cohort of women with cardiac disease, blood loss
was lower than that described by others. Kaoutrolou-sotir-
opoulou reported on a mixed population of congenital
and acquired cardiac disease and women without cardiac
disease [9]. There was no difference in blood loss between
women with and without cardiac disease. However, the
mean blood loss for both groups was approximately 500
mLs with a standard deviation of approximately 350mL,
compared to an arithmetic mean of 301mL ± 230mL in
our cohort. As blood loss was not subcategorised according
to mode of delivery in their study, it was not possible to as-
certain if excess blood loss was associated with mode of de-
livery. The arithmetic mean EBL for women with cardiac
disease in our cohort was also lower than that of a previ-
ously published cohort of women with and without con-
genital heart disease for all modes of delivery [6].
Strengths
Our study has a number of key strengths. Firstly, the use
of computerised hospital records enabled us to obtain
accurate information regarding uterotonics used and
mode of delivery. We employed a number of cross refer-
encing strategies to capture adverse outcomes, such as
unexpected admission to the high dependency unit and
blood transfusion rates, and were able to report these for
our cardiac cohort.
Limitations
Our study has a number of limitations. Firstly, we used
subjectively estimated blood loss and did not weigh
swabs or drapes to measure actual blood loss. Therefore,
it is possible that blood loss was under or overestimated.
However, given that this practice would also apply to the
low risk cohort, the effect of over or underestimating
blood loss would be negated. Secondly, we lacked de-
tailed data on anti-coagulant usage in the cardiac disease
cohort. Although the recommended advice is to cease
low molecular weight heparin (LWMH) use as soon as
labour starts, we are unable to provide time intervals be-
tween the last dose of administration of LMWH to time
of delivery, and whether this may have affected the EBL.
However, since there was no difference in blood loss be-
tween the control and cardiac groups, it is unlikely that
LMWH use had a significant impact on blood loss. In a
recent study on women with mechanical heart valves, a
population of women thought to be most at risk of
bleeding, due to anticoagulation use, the incidence of
primary PPH was low (2%) [10]. Thirdly, we did not have
detailed information on blood pressure changes following
intravenous oxytocin administration. However, there were
no unexpected admissions to the high dependency unit,
and no patient required non-blood product fluid resusci-
tation as direct consequence of intravenous or intramus-
cular oxytocin administration. Finally, our cohort included
only three women in the mWHO 4 category, where preg-
nancy is ordinarily contraindicated. Though these three
women did not experience adverse effects following intra-
venous oxytocin administration, caution is advised in this
high risk population due to the potential for acute haemo-
dynamic changes secondary to intravenous oxytocin ad-
ministration. Care should always be individualized within
a multidisciplinary team setting.
There is a paucity of evidence to guide the use of utero-
tonics in the third stage of labour in women with heart
disease. As a result, concerns about the potential cardio-
vascular effects of oxytocin have led to some units avoid-
ing its use completely [11], or using low dose regimes [6]
with parallel increased blood loss. Cauldwell et al. under-
took a prospective cohort study in women with congenital
and acquired heart disease to evaluate differing regimes of
oxytocin in the third stage, and its impact on cardiovascu-
lar parameters [2]. In their study, one group of 30 women
received 12 mUnits/min for 4 h in accordance with the
RCOG recommendations for women with cardiac disease,
which is their “standard” practice.1,2 Another group of 30
women received 2 i.u. oxytocin given iv over 10min in
addition to their “standard” regime. In the “standard” re-
gime group, the mean EBL was 830mL + 444mL, and in
the intervention group, the mean EBL was 511 + 328mL.
Even their ‘high’ dose oxytocin regime was lower than the
standard dose given to healthy women, and the mean EBL
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for both groups of women was greater than in our cohort
of women with cardiac disease managed with standard
uteronic care. Specialized drapes to collect blood loss in
the Cauldwell study may have improved the accuracy of
blood loss, whereas we employed visual estimation of
blood loss, an internationally recognized standard albeit
with its limitations. Future studies could employ spectro-
photometry, considered the “gold standard” for quantify-
ing blood loss in a research context [8].
It is particularly important to minimise blood loss in
women with heart disease: those with a preload dependent
circulation or an inability to increase cardiac output are at
risk of cardiovascular collapse if PPH occurs, and those
who require anticoagulation for their heart disease are at
inherently higher risk of bleeding. Thus, meticulous care
to minimise blood loss around the time of delivery is im-
portant to achieving a good maternal outcome.
Conclusions
Our study demonstrates that active management of the third
stage in line with NICE guidelines for women without car-
diac disease may be administered safely to women with a
broad spectrum of heart disease. This resulted in a low esti-
mated blood loss that was comparable to low risk women
without heart disease. Our population consists of women
with heart disease in a very specialised unit that has a range
of particularly high risk and complex congenital and ac-
quired heart conditions and is, therefore, not representative
of most obstetric units. Nonetheless, our findings suggest
that in women with cardiac disease, an infusion of 5 i.u oxy-
tocin over 10min or 10 i.u. intramuscularly may be adminis-
tered without clinically relevant adverse effects. In doing so,
blood loss after delivery and the consequences of postpartum
haemorrhage can be minimised. However, careful cardiovas-
cular monitoring is still advisable in some cases, and care
individualised, as there may be some that are unusually in-
tolerant of the cardiovascular effects of oxytocin.
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